A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR

Investigational site, Blagoevgrad

Investigational site, Pazardzhik

Investigational site, Pleven

Investigational site, Plovdiv

Investigational site, Rousse

Investigational site, Sofia

Investigational site, Varna

Investigational site, České Budějovice

Investigational site, Český Krumlov

Investigational site, Karlovy Vary

Investigational site, Ostrava

Investigational site, Ostrava-Vitkovice

Investigational site, Prague

Investigational site, Slaný

Investigational site, Znojmo

Investigational site, Baja

Investigational site, Budapest

Investigational site, Debrecen

Investigational site, Eger

Investigational site, Kistelek

Investigational site, Komárom

Investigational site, Pécs

Investigational site, Szigetvár

Investigational site, Szikszó

Investigational site, Zalaegerszeg

Investigational site, Krakow

Investigational site, Ruda Śląska

Investigational site, Rzeszów

Investigational site, Świętochłowice

Investigational site, Bacau

Investigational site, Brăila

Investigational site, Bucharest

Investigational site, Buzău

Investigational site, Cluj-Napoca

Investigational site, Deva

Investigational site, Iași

Investigational site, Oradea

Investigational site, Ploiesti, Judet Prahova

Investigational site, Satu Mare

Investigational site, Târgu Mureş

Investigational site, Timișoara

Investigational site, Bardejov

Investigational site, Bratislava

Investigational site, Levice

Investigational site, Lučenec

Investigational site, Martin

Investigational site, Nitra

Investigational site, Prešov

Investigational site, Šahy

Investigational site, Štúrovo